|
|
 Previous Article | Table of Contents | Next Article 
Treatment of acute lymphoblastic leukemia in adults with intensive
induction, consolidation, and maintenance chemotherapy
KK Hussein, S Dahlberg, D Head, CC Waddell, L Dabich, JK Weick, F Morrison, JH Saiki, E Metz and SE Rivkin
University of Oklahoma Health Sciences Center, Oklahoma City.
The Southwest Oncology Group conducted a study of acute lymphoblastic
leukemia (ALL) in adults over a 5-year period, testing the utility of the
L-10M regimen initially described by the group from Memorial Sloan-
Kettering Cancer Center. One hundred sixty-eight eligible patients were
treated with this intensive combination chemotherapy regimen. One hundred
fifteen (68%) achieved complete remission. With the current median
follow-up time of 34.5 months, the median durations of remission,
relapse-free survival, and overall survival were 22.9, 20.9, and 17.7
months, respectively. Only 35% of the patients over 50 years of age
achieved a complete remission. Age was a significant prognostic factor for
complete response, survival, relapse-free survival, and remission duration.
In addition, a low initial WBC count was found to have a statistically
significant association with longer remission duration. Responders between
the ages of 20 and 49 years with WBC counts of less than 15,000 appear to
have an exceptionally good prognosis.
Volume 73,
Issue 1,
pp. 57-63,
01/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. M. Lazarus, S. M. Richards, R. Chopra, M. R. Litzow, A. K. Burnett, P. H. Wiernik, I. M. Franklin, M. S. Tallman, L. Cook, G. Buck, et al.
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993
Blood,
July 15, 2006;
108(2):
465 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Jabbour, S. Faderl, and H. M. Kantarjian
Adult Acute Lymphoblastic Leukemia
Mayo Clin. Proc.,
November 1, 2005;
80(11):
1517 - 1527.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Linker, L. Damon, C. Ries, and W. Navarro
Intensified and Shortened Cyclical Chemotherapy for Adult Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
May 15, 2002;
20(10):
2464 - 2471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Annino, M. L. Vegna, A. Camera, G. Specchia, G. Visani, G. Fioritoni, F. Ferrara, A. Peta, S. Ciolli, W. Deplano, et al.
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study
Blood,
February 1, 2002;
99(3):
863 - 871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kantarjian, S. O’Brien, T. L. Smith, J. Cortes, F. J. Giles, M. Beran, S. Pierce, Y. Huh, M. Andreeff, C. Koller, et al.
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
J. Clin. Oncol.,
February 1, 2000;
18(3):
547 - 547.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Weisdorf, A. L. Billett, P. Hannan, J. Ritz, S. E. Sallan, M. Steinbuch, and N. K.C. Ramsay
Autologous Versus Unrelated Donor Allogeneic Marrow Transplantation for Acute Lymphoblastic Leukemia
Blood,
October 15, 1997;
90(8):
2962 - 2968.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
